Question special
Lead Moderator

For the final question, I was hoping that we could discuss the real world phase 3b-4 study "Prospective, open-label study of andexanet alfa in patients receiving a factor Xa inhibitor who have acute major bleeding." What is the design, dosing, and why is it so important to have real world data before using this agent to reverse apixaban and rivaroxaban.